Unknown

Dataset Information

0

Prognostic significance of nephrectomy in metastatic renal cell carcinoma treated with systemic cytokine or targeted therapy: A 16-year retrospective analysis.


ABSTRACT: We compared progression-free survival (PFS) and overall survival (OS) among 292 metastatic renal cell carcinoma (mRCC) patients either undergoing nephrectomy (Nx, 61.6%) or not (non-Nx, 38.4%), stratified according to the MSKCC and Heng risk models, treated with either immunotherapy (IT, 45.2%) or targeted therapy (TT, 54.8%) between 2000 and 2015. During the follow-up duration of 16.6 months, PFS/OS of the Nx (6.0/30 months) and non-Nx (3.0/6.0 months) groups were significantly different despite differences among baseline parameters (p??0.05). In both synchronous and metachronous mRCC patients, both PFS and OS showed similar survivals; the Nx group had significantly longer PFS and OS than the non-Nx group, even after considering each systemic therapy and prognostic model. Nx showed a significant positive benefit in PFS and OS compared to no Nx upon patient stratification according to the MSKCC and Heng risk models. The metastatic type did not significantly affect survival between the two groups.

SUBMITTER: Kim SH 

PROVIDER: S-EPMC5813006 | BioStudies | 2018-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5564792 | BioStudies
2019-01-01 | S-EPMC6382149 | BioStudies
2019-01-01 | S-EPMC6538800 | BioStudies
2020-01-01 | S-EPMC7052413 | BioStudies
2014-01-01 | S-EPMC3956829 | BioStudies
2016-01-01 | S-EPMC4720089 | BioStudies
2017-01-01 | S-EPMC5725002 | BioStudies
1000-01-01 | S-EPMC5646127 | BioStudies
1000-01-01 | S-EPMC5706824 | BioStudies
2015-01-01 | S-EPMC4320862 | BioStudies